Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo‐controlled, phase I study in healthy volunteers

AIMS: Myeloperoxidase activity can contribute to impaired vascular endothelial function and fibrosis in chronic inflammation‐related cardiovascular disease. Here, we investigated the safety, tolerability and pharmacokinetics of the myeloperoxidase inhibitor, AZD4831. METHODS: In this randomized, sin...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Br J Clin Pharmacol
Egile Nagusiak: Gan, Li‐Ming, Lagerström‐Fermér, Maria, Ericsson, Hans, Nelander, Karin, Lindstedt, Eva‐Lotte, Michaëlsson, Erik, Kjaer, Magnus, Heijer, Maria, Whatling, Carl, Fuhr, Rainard
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2019
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6422671/
https://ncbi.nlm.nih.gov/pubmed/30618054
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13855
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak